Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15330789 | 0.85 | NPSR1 (0.51) | NPSR1MAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL12531935 | 0.78 | CYP1A2 (0.64) | NPSR1MAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL11282667 | 0.75 | NPSR1 (0.52) | NPSR1MAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL7256405 | 0.75 | NPSR1 (0.79) | NPSR1MAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL14129601 | 0.73 | NPSR1 (0.50) | NPSR1MAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL4804422 | 0.73 | SMN1; SMN2 (0.68) | NPSR1MAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL16506763 | 0.73 | NPSR1 (0.50) | NPSR1MAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL24761236 | 0.73 | MEN1 (0.41) | NPSR1ALDH1A1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL9737749 | 0.73 | SMN1; SMN2 (0.38) | NPSR1MAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL7482811 | 0.72 | NPSR1 (0.62) | NPSR1MAPTALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-1254907-B1 | PYRROLOPYRIDAZINE COMPOUND | SANKYO CO (JP) | 2007-05-09 | — | — | EP | disclosed |
| US-6734181-B2 | GASTRIC ACID SECRETORY INHIBITION ACTIVITY, GASTRIC MUCOUS MEMBRANE PROTECTION ACTIVITY; TREATMENT OF ULCERS AND HELICOBACTER PYLORI INFECIONS | SANKYO COMPANY, LIMITED (JP) | 2004-05-11 | — | — | US | disclosed |
| US-20040014762-A1 | Pyrrolopyridazine compounds | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| US-6670360-B2 | Antiulcer, antibacterial activity against Helicobacter pylori | SANKYO COMPANY, LIMITED (JP) | 2003-12-30 | — | — | US | disclosed |
| EP-1186607-B1 | OPTICALLY ACTIVE PYRROLOPYRIDAZINE COMPOUNDS | SANKYO CO (JP) | 2003-05-21 | — | — | EP | disclosed |
| EP-0742218-B1 | PYRROLOPYRIDAZINE DERIVATIVE | SANKYO CO (JP) | 2002-12-04 | — | — | EP | disclosed |
| EP-1254907-A1 | PYRROLOPYRIDAZINE COMPOUND | Sankyo Company, Limited (JP) | 2002-11-06 | — | — | EP | disclosed |
| US-20020156079-A1 | Optically active pyrrolopyridazine derivatives | SANKYO COMPANY, LIMITED (JP) | 2002-10-24 | — | — | US | disclosed |
| EP-1186607-A1 | OPTICALLY ACTIVE PYRROLOPYRIDAZINE COMPOUNDS | Sankyo Company, Limited (JP) | 2002-03-13 | — | — | EP | disclosed |
| US-6063782-A | Pyrrolopyridazine derivatives | SANKYO COMPANY, LIMITED (JP) | 2000-05-16 | — | — | US | disclosed |
| EP-0742218-A1 | PYRROLOPYRIDAZINE DERIVATIVE | SANKYO COMPANY LIMITED (JP) | 1996-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156079-A1 | Optically active pyrrolopyridazine derivatives | GIPR, HRH2, PGA5 | NPSR1 2370/4885MAPT 4805/4885ALDH1A1 74/4885 |
| US-20040014762-A1 | Pyrrolopyridazine compounds | HRH2, ADH1C, GIPR | NPSR1 3769/4885MAPT 4872/4885ALDH1A1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.